Dudediligence.

Arrowhead Pharmaceuticals, Inc

ARWRNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$2.5MDec ’24$542.7MMar ’25$27.8MJun ’25$256.5MSep ’25$264.0MDec ’25$73.7MMar ’26$75.3MJun ’26
Net income, by quarter
−$170.5MSep ’24−$173.1MDec ’24$370.4MMar ’25−$175.2MJun ’25−$23.8MSep ’25$30.8MDec ’25−$132.7MMar ’26−$194.3MJun ’26
Fiscal years, by the month each ended
LineSep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Revenue$138.3M$243.2M$240.7M$3.6M$829.4M
Operating income−$149.0M−$178.5M−$205.0M−$601.1M$98.3M
Net income−$140.8M−$176.1M−$205.3M−$599.5M−$1.6M
Operating cash flow$171.3M−$136.1M−$153.9M−$462.9M$179.6M
Free cash flow$147.7M−$188.9M−$330.6M−$604.3M$156.9M
Cash$184.4M$108.0M$110.9M$102.7M$226.5M
Shares outstanding104.3M106.0M107.3M124.4M135.7M